MX2020006884A - Metodos de purificacion de virus adenoasociado. - Google Patents

Metodos de purificacion de virus adenoasociado.

Info

Publication number
MX2020006884A
MX2020006884A MX2020006884A MX2020006884A MX2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A
Authority
MX
Mexico
Prior art keywords
adeno
associated virus
purification methods
virus purification
aav
Prior art date
Application number
MX2020006884A
Other languages
English (en)
Spanish (es)
Inventor
Meinhard Hasslacher
Christian Fiedler
Jadranka Koehn
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020006884A publication Critical patent/MX2020006884A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020006884A 2017-12-29 2018-12-27 Metodos de purificacion de virus adenoasociado. MX2020006884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611709P 2017-12-29 2017-12-29
PCT/US2018/067627 WO2019133677A1 (en) 2017-12-29 2018-12-27 Adeno-associated virus purification methods

Publications (1)

Publication Number Publication Date
MX2020006884A true MX2020006884A (es) 2020-10-01

Family

ID=67064154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006884A MX2020006884A (es) 2017-12-29 2018-12-27 Metodos de purificacion de virus adenoasociado.

Country Status (12)

Country Link
US (1) US11981934B2 (cg-RX-API-DMAC7.html)
EP (1) EP3731863A4 (cg-RX-API-DMAC7.html)
JP (2) JP7299896B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200106045A (cg-RX-API-DMAC7.html)
CN (1) CN111655285B (cg-RX-API-DMAC7.html)
AU (1) AU2018395254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020013197A8 (cg-RX-API-DMAC7.html)
CA (1) CA3084827A1 (cg-RX-API-DMAC7.html)
IL (1) IL275533B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006884A (cg-RX-API-DMAC7.html)
SG (1) SG11202006232SA (cg-RX-API-DMAC7.html)
WO (1) WO2019133677A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013953A (es) * 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
US20220267796A1 (en) * 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
EP3868886A1 (en) * 2020-02-21 2021-08-25 Bia Separations D.O.O. A method for separation or depletion of empty aav capsids from full aav capsids
US20220033782A1 (en) * 2020-07-29 2022-02-03 Pall Corporation Adenovirus-associated viruses separation method
CN116234619B (zh) * 2020-08-18 2026-07-21 赛多利斯比亚分离有限责任公司 宿主细胞dna的金属亲和提取
AU2021375404A1 (en) * 2020-11-03 2023-06-08 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
CN116802308A (zh) * 2020-11-03 2023-09-22 辉瑞公司 通过阴离子交换色谱法纯化aav载体的方法
JP2023550799A (ja) * 2020-11-24 2023-12-05 ザルトリウス ビーアイエー セパレーションズ ディー.オー.オー. アフィニティークロマトグラフィーのための改善された洗浄方法
JP2024503234A (ja) * 2020-12-23 2024-01-25 ファイザー・インク 親和性クロマトグラフィーによるaavベクターの精製方法
CA3205744A1 (en) * 2021-01-21 2022-07-28 Tamara ZEKOVIC Method for purifying recombinant viral particles
CN114591921B (zh) * 2022-03-31 2024-08-02 上海勉亦生物科技有限公司 腺相关病毒的纯化方法和洗脱液
WO2022222869A1 (zh) * 2021-04-19 2022-10-27 信念医药(香港)有限公司 重组腺相关病毒及其应用
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
WO2023077085A2 (en) * 2021-10-29 2023-05-04 Oxford Biomedica Solutions Llc Methods and compositions for the purification of adeno-associated virus
JP2023098806A (ja) * 2021-12-29 2023-07-11 東ソー株式会社 アデノ随伴ウイルスの精製方法
CN114350622A (zh) * 2022-01-17 2022-04-15 苏州博腾生物制药有限公司 一种病毒纯化高效保护试剂及其应用
US20250188120A1 (en) 2022-03-07 2025-06-12 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
GB202206123D0 (en) * 2022-04-27 2022-06-08 Cytiva Bioprocess R & D Ab A pre-screening method and a method for separating adeno-associated virus capsids
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
KR20260049579A (ko) * 2023-08-01 2026-04-14 메르크 파텐트 게엠베하 개선된 용리 시스템의 음이온 교환 크로마토그래피를 사용한 aav 입자의 연마
CN122249270A (zh) * 2023-11-16 2026-06-19 赛多利斯比亚分离有限责任公司 通过采用络合剂递减梯度增强混合物中组分的色谱分离
WO2025207456A1 (en) * 2024-03-25 2025-10-02 Frontera Therapeutics, Inc. Methods for purification of adeno associated virus particles by anion exchange chromatography
WO2026077794A1 (en) * 2024-10-07 2026-04-16 Cytiva Us Llc Plasmid purification methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543363A (en) 1983-06-15 1985-09-24 Asahi Kasei Kogyo Kabushiki Kaisha Ion exchanger having hydroxyl groups bonded directly to backbone skeleton
SE9902133D0 (sv) 1999-06-06 1999-06-06 Amersham Pharm Biotech Ab A method for surface modification, a novel support matrix and the use of the matrix
GB9925432D0 (en) * 1999-10-27 1999-12-29 Univ London Virus preparation
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
JP5956331B2 (ja) * 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えaavベクターの改良された精製方法
MX379269B (es) * 2012-10-24 2025-03-11 Genzyme Corp Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.
CN104232687A (zh) * 2014-09-17 2014-12-24 许瑞安 一种重组腺相关病毒rAAV载体的分离纯化方法
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US11015174B2 (en) * 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
EP3387138B2 (en) * 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US12564816B2 (en) 2019-11-21 2026-03-03 Merck Millipore Ltd. Hydrophilic membranes

Also Published As

Publication number Publication date
IL275533B2 (en) 2025-03-01
JP2021508484A (ja) 2021-03-11
CN111655285A (zh) 2020-09-11
AU2018395254B2 (en) 2024-07-25
BR112020013197A2 (pt) 2021-02-17
IL275533B1 (en) 2024-11-01
IL275533A (en) 2020-08-31
RU2020124946A3 (cg-RX-API-DMAC7.html) 2022-02-08
WO2019133677A1 (en) 2019-07-04
BR112020013197A8 (pt) 2022-11-08
EP3731863A1 (en) 2020-11-04
RU2020124946A (ru) 2022-01-31
US11981934B2 (en) 2024-05-14
JP7299896B2 (ja) 2023-06-28
AU2018395254A1 (en) 2020-06-25
JP7531654B2 (ja) 2024-08-09
KR20200106045A (ko) 2020-09-10
CA3084827A1 (en) 2019-07-04
US20200332266A1 (en) 2020-10-22
EP3731863A4 (en) 2021-10-27
CN111655285B (zh) 2025-02-25
JP2023089298A (ja) 2023-06-27
SG11202006232SA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
BR112020013197A8 (pt) Métodos de purificação de vírus adenoassociado
AU2018260998A1 (en) Modulatory polynucleotides
EP4585229A3 (en) Means and method for preparing viral vectors and uses of same
PH12020500044A1 (en) Aav vector column purification methods
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
EP4234688A3 (en) Adeno-associated virus purification methods
WO2019241535A3 (en) Anion exchange chromatography for recombinant aav production
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
WO2016018740A8 (en) Purification platform for bispecific antibodies
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
NZ737796A (en) Anti-tau antibodies and methods of use
WO2016012285A3 (en) Method
PH12018502104B1 (en) Column-based fully scalable raav manufacturing process
HK1244299A1 (zh) 治疗肌萎缩侧索硬化(als)的组合物和方法
AU2020299026A8 (en) Methods and AAV vectors for in vivo transduction
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP4413996A3 (en) Novel antibodies against factor xi and uses thereof
EP3533825A4 (en) ORGANIC-INORGANIC COMPOSITE FOR REINFORCING RUBBER, MANUFACTURING METHOD THEREFOR AND TIRE RUBBER COMPOSITION THEREFOR
EP3245218A4 (en) Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3880695A4 (en) ACTIVIN/BMP7 CHIMERA: SUPERACTIVE SAB704 AND SAB715 AND THEIR RESPECTIVE NOGGIN-SENSITIZED VARIANTS, NAB704 AND NAB715 AND NAB204
IL284402A (en) A process for the production, isolation and purification of modified recombinant proteins

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED